Program
Ranolazine
Also written as “Test formulation (Ranolazine extended-release tablets)”, “Reference formulation (Ranolazine extended-release tablets)” and “Ranolazine 500 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Angina Pectoris · Atrial Fibrillation · Coronary Artery Disease · Cardiovascular Diseases, led by 7 companies.
Drug pageRanolazine: every studyMany companies study it; this page follows only the 25 they lead. All 85 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 180 open or running | phase 4since Mar 24, 2008 | Sep 8, 2004 | none ahead |
| Menarini Groupits history only | 20 open or running | phase 2since Feb 10, 2012 | Feb 10, 2012 | none ahead |
| Amit Malhotra, MDits history only | 10 open or running | phase 4since Jan 26, 2017 | Jan 26, 2017 | none ahead |
| Haisco Pharmaceutical Groupits history only | 10 open or running | phase 1since Jun 27, 2025 | Jun 27, 2025 | none ahead |
| Novartisits history only | 10 open or running | phase 2since Mar 21, 2012 | Mar 21, 2012 | none ahead |
| OBS Pakistanits history only | 10 open or running | phase 4since Mar 15, 2018 | Mar 15, 2018 | none ahead |
| TSH Biopharmits history only | 10 open or running | no phasesince Jan 7, 2018 | Jan 7, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Sep 8, 2004.
- Mar 24, 2008Phase 4 study in Chronic AnginaNCT00644332 · 172 enrolled · United States
- Jan 28, 2009Phase 4 study in Coronary Artery DiseaseNCT00832572 · 5 enrolled · United States
- Jul 12, 20102 phase 2 studiesNCT01163734, NCT01163721
- Oct 13, 2010Phase 4 study in Myocardial IschemiaNCT01221272 · 81 enrolled · United States, Canada, Czech Republic and more
- Apr 11, 2011Phase 4 study in Angina PectorisNCT01334203
- Aug 24, 2011Phase 4 study in Angina PectorisNCT01425359 · 949 enrolled · United States, Belarus, Bulgaria and more
- Sep 22, 2011Phase 3 study in Coronary Artery DiseaseNCT01442038 · 2,651 enrolled · United States, Austria, Belgium and more
- Nov 11, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01472185 · 465 enrolled · United States, Czech Republic, Hungary and more
- Dec 15, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01494987 · 431 enrolled · United States, Czech Republic, Hungary and more
- Jan 18, 2012Phase 2 study in Atrial FibrillationNCT01522651 · 134 enrolled · United States, Germany, Israel and more
- Feb 14, 20122 phase 1 studies in Diabetes Mellitus, Type 2NCT01546597, NCT01546558
- Mar 13, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01555164 · 442 enrolled · United States, Canada, Czech Republic and more
- Jul 26, 2012Phase 1 study in Renal InsufficiencyNCT01675973 · 4 enrolled · United States
- Apr 17, 2013Phase 1 study in Diabetes Mellitus, Type 2NCT01843127 · 24 enrolled · United States
TargetBeta
“Sodium channel protein type V alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Quinidinerule | Otsuka | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 18 Gilead Sciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01843127Diabetes Mellitus, Type 2 · United States | 1 | Completed | Sep 2013 | 24 |
| NCT01675973Renal Insufficiency · United States | 1 | Terminated | Aug 2012 | 4 |
| NCT01555164Diabetes Mellitus, Type 2 · United States, Canada, Czech Republic and more | 3 | Completed | Sep 2013 | 442 |
| NCT01546558Diabetes Mellitus, Type 2 · United States | 1 | Completed | Mar 2012 | 25 |
| NCT01546597Diabetes Mellitus, Type 2 · United States | 1 | Completed | Mar 2012 | 24 |
| NCT01522651Atrial Fibrillation · United States, Germany, Israel and more | 2 | Completed | Mar 10, 2014 | 134 |
| NCT01494987Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more | 3 | Completed | Aug 2013 | 431 |
| NCT01472185Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more | 3 | Completed | Oct 2013 | 465 |
| NCT01442038Coronary Artery Disease · United States, Austria, Belgium and more | 3 | Completed | Feb 2015 | 2,651 |
| NCT01425359Angina Pectoris · United States, Belarus, Bulgaria and more | 4 | Completed | Oct 2012 | 949 |
| NCT01334203Angina Pectoris | 4 | Withdrawn | Oct 2012 | 0 |
| NCT01221272Myocardial Ischemia · United States, Canada, Czech Republic and more | 4 | Completed | Sep 2012 | 81 |
| NCT01163721Diabetes Mellitus, Type 2 · United States | 2 | Completed | Nov 2010 | 80 |
| NCT01163734Heart Failure, Diastolic · Germany | 2 | Completed | Feb 2011 | 20 |
| NCT00832572Coronary Artery Disease · United States | 4 | Terminated | Jun 2009 | 5 |
| NCT00644332Chronic Angina · United States | 4 | Completed | Jan 2011 | 172 |
| NCT00099788Myocardial Ischemia · United States | 3 | Completed | Feb 2007 | 6,560 |
| NCT00091429Angina Pectoris | 3 | Completed | Feb 2005 | 500 |
How it is read
Names in the registry
- “Ranolazine”, 24 entries
- “Test formulation (Ranolazine extended-release tablets)”, 1 entry
- “Reference formulation (Ranolazine extended-release tablets)”, 1 entry
- “Ranolazine 500 mg”, 1 entry
- “Ranolazine plus Metoprolol Combination”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 7 studies
- Angina Pectoris, 5 studies
- Atrial Fibrillation, 3 studies
- Coronary Artery Disease, 2 studies
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.